A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

J1G-MC-LAKA -

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD. The study has two parts: Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks and Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.

Trial Summary

Age Range
18 - 85 years
Conditions the trial is for
Alzheimer's Disease
What the trial is testing?
LY3372993
Could I receive a Placebo?
Yes
Enrollment Goal
36
Trial Dates
Nov 5, 2018 - May 14, 2019
How long will I be in the trial?
Part A will last up to 17 weeks and may include up to 14 visits. Part B will last up to 317 days and may include 16 visits.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.